Sector News

Stryker to spend up to $500M to boost spine unit with imaging, robotics tech

September 5, 2019
Life sciences

Stryker follows a slew of medtechs that have aimed to deepen their robotic surgery capabilities this year through acquisitions: Johnson & Johnson bought out Auris Health for $3.4 billion, Intuitive Surgical added Schölly Fiberoptic’s robotic endoscope business, and Siemens Healthineers last month purchased Corindus Vascular Robotics.

The acquisition is also the third announced by Stryker this year, with the company having previously picked up chronic rhinitis device maker Arrinex and rotator cuff tear tech company OrthoSpace. Canadian hospital sterilization product manufacturer TSO3 also last month said it had agreed to be acquired by Stryker.

The deal announced Wednesday is the second major medtech exit for Mobius CEO and co-founder Eugene Gregerson, who previously co-founded Breakaway Imaging, which sold its O-arm imaging system to Medtronic’s surgical navigation systems business in 2007.

Stryker’s presence in robotics has been mostly centered on its Mako joint replacement platform for total knee, partial knee and total hip procedures, technologies acquired through its $1.65 billion buyout of Mako Surgical in 2013. Stryker said the product line helped drive its recent 9.9% growth in net sales during the second quarter. The expansion into other robotic surgery technologies comes as Zimmer Biomet’s Rosa robotic surgery platform has begun to take share in some of Mako’s specialties.

Neurotechnology and Spine, Stryker’s smallest division, had 7.4% organic growth last quarter. The company made a major investment in the unit last year with the $1.4 billion acquisition of spinal surgery device maker K2M. The strategy of bolstering spine device sales by enhancing spine surgery platforms appears to be working for at least one competitor; Medtronic reported a bump to its spine implant sales in the most recent quarter thanks to adoption of its Mazor robotic surgery platform.

Stryker anticipates the deal will close in the fourth quarter of 2019 and does not expect it to have material impact on full-year net earnings.

By Maria Rachal

Source: MedTechDive

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”